DOCSLIB.ORG

2012 Conference Proceedings

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2012 Conference Proceedings Scientific Program Sunday 2 December, 2012 10:00 – 12:00 Parkside G04 PGx: new research interests and directions workshop 14:30 – 16:30 Parkside 110A Parkside G04 Parkside 110B ASCEPT-APSA Careers workshop ASCEPT-APSA Clinical ASCEPT-APSA Education Careers in the pharmaceutical industry Pharmacology workshop Forum workshop Chairs Dr Barbara Kemp-Harper, Introduction to TDM/TCI Introduction and scene setting; TEQSA; Ms Claire Johnston, Ms Alice Kane Dr Matt Doogue Standards Panel and TLOs Finding your way in the Pharmaceutical Measuring drug concentrations, analytical Prof Ieva Stupans, University of New Industry methods and issues England Dr Annette Gross, GlaxoSmithKline R&D Dr Andrew Rowland Mapping assessment to TLOs for pharmacy It’s a long way from rats and lab coats Digoxin, a classic Prof Ieva Stupans, University of New Dr Richard Booth, iNOVA Pharmaceuticals Prof Ray Morris England What I wish I knew about clinical trials The perhexiline story What is the relevance of TLOs for the roles and networking when I was sitting Prof John Horowitz teaching of pharmacology? where you are today! Dr Liz Davis, Monash University and Dr Dr Craig Rayner, Roche Tina Hinton, The University of Sydney How to locate and maximise your success in finding your ideal job Dr Amanda Reid, Daryl Alexander & Associates 17:00 – 18:00 Parkside Auditorium Welcome to country Opening session and plenary 1 Prof David Le Couteur, ASCEPT President Prof Andrew McLachlan, APSA President Emeritus Prof Kim Oates AM, The University of Sydney 18:00 – 19:30 Welcome Reception Parkside Foyer, Level 1 Monday 3 December, 2012 08:00 – 09:00 Parkside Foyer, Level 1 Poster presentations SPONSORED BY 09:00 – 10:00 Parkside Auditorium Plenary 2: British Pharmacological Society lecture Proton pump inhibitors - robust evidence of public health hazard, or just plain confounding? - 101 Dr Yoon Loke, The University of East Anglia, UK 10:00 – 10:30 Morning tea 10:30 – 12:30 Parkside Auditorium Parkside 110A Parkside 110B Parkside G04 Symposium 1: Symposium 2: Symposium 3: Symposium 4: Drug transporters in clinical The yin and yang of novel Emerging trends in dose The patient journey pharmacokinetics and drug-drug receptor drug discovery individualisation in clinical interactions paradigms practice Chairs Dr Joseph Nicolazzo Dr Meritxell Canals Buj A/Prof Ross Norris Prof Ines Krass A/Prof Betty Sallustio Transporter-based drug-drug Inflammation resolution Non-parametric population The patient journey towards the interactions – principles and mediators in tumour growth PK models and their use in end of life-patient and family examples - 102 and metastasis: good, bad and individual patient care - 110 accounts of patient safety - 114 Prof Jashvant Unadkat, indifferent - 106 A/Prof Michael Neely, University Ms Aileen Collier, Centre University of Washington, USA Prof Alastair Stewart, The of Southern California, USA for Health Communication, Role of organic cation University of Melbourne Emerging trends in dose University of Technology Sydney transporters in mediating oral Exploring allosteric modulation individualisation in clinical Towards a medicinewise drug absorption - 103 and ligand-directed stimulus practice - 111 Australia: the NPS approach to Dr Dhiren Thakker, University of bias at the glucagon-like A/Prof Jennifer Martin, The improving health literacy - 115 North Carolina, USA peptide-1 receptor - 107 University of Queensland Ms Karen Kaye, NPS Role of transporters in mediating Denise Wootten, Monash Pharmacogenomics in dose Medicinewise hepatobiliary clearance of drugs University individualisation - 112 - 104 Physiological correlates of Prof Elizabeth Phillips, Institute Prof Kim Brouwer, University of biased receptor signalling: for Immunology & Infectious North Carolina, USA relevance to opioid drug action Diseases Impact of BBB Transporters in health and disease - 108 Dose individualisation of on Delivery and Efficacy of Dr Laura Bohn, The Scripps Dabigatrin - 113 Molecularly-Targeted Agents in Research Institute, Florida, USA Dr Paul Chin, University of Brain Tumors - 105 Revealing the potential of GPCR Otago, NZ Prof William Elmquist, University bias signalling - 109 of Minnesota, USA Prof Andrew Tobin, University of Leicester, UK 1 Monday 3 December, 2012 cont. 12:30 – 13:30 Parkside Foyer, Level 1 Lunch and poster presentations Parkside Auditorium Parkside G04 Parkside 110B Parkside 110A Meetings: Pharmacogenomics SIG New Zealand Forum Toxicology and Drug Discovery Neuro- behavioural SIG SIG 13:30 – 15:30 Parkside 110B Parkside Auditorium Parkside G04 Parkside 110A Oral presentations 1 Oral presentations 2 Oral presentations 3: Oral presentations 4 Clinical Trainee Chairs Dr Betty Exintaris A/Prof Lynne Emmerton Dr Matt Doogue Dr David Shackleford 13:30 – 13:45 The effect of ageing on What parents want to know about Is the process for approval of Differential effects of mango paracetamol pharmacokinetics attention-deficit hyperactivity high cost drugs for off-formulary peel sub-fractions on lipid and toxicity in Fischer 344 rats disorder (ADHD)- A qualitative use leading to clinically accumulation in 3T3-L1 - 120 investigation - 128 appropriate outcomes? - 136 adipocyte cells - 144 Mr John Mach, Kolling Institute Miss Rana Ahmed, The Faculty Dr Catherine Lucas, Department Mr Meng-Wong Taing, School of Medical Research, Royal of Pharmacy, The University of of Clinical Pharmacology, Royal of Pharmacy, The University of North Shore Hospital, Sydney Sydney Brisbane and Women’s Hospital Queensland Medical School, The University of Sydney 13:45 – 14:00 NOX2ß: A Novel Splice Variant The influence of disease and The performance of the The preparation and of NOX2 That Promotes other factors on adherence - 129 Cockcroft-Gault, MDRD and characterisation of polypyrrole Reactive Oxygen Species (ROS) Miss Piyanan CKD-EPI equations in predicting particles for tuneable drug Production in Macrophages - Assawasuwannakit, School of gentamicin clearance - 137 delivery - 145 121 Pharmacy, University of Otago, Dr Paul Chin, Department Mr Zaid Aqrawe, The University Dr Stavros Selemidis, NZ of Clinical Pharmacology, of Auckland, NZ Department of Pharmacology, Christchurch Hospital, NZ, Monash University Department of Medicine, University of Otago, NZ 14:00 – 14:15 Bitter taste receptor agonists are Strategies used to support Describing the use of antibiotics Characterisation of emulsions novel bronchodilators of small patients’ adherence to in acute exacerbations of as potential saliva substitutes in airways in mouse lung slices medication: a national survey of chronic obstructive pulmonary xerostomia - 146 - 122 community pharmacists - 130 disease - 138 Miss Sara Hanning, School of Dr Jane Bourke, Dept of Mrs Sarab Mansoor, Faculty of Dr Mitchell McKean, Princess Pharmacy, University of Otago, Pharmacology, University of Pharmacy, The University of Alexandra Hospital NZ Melbourne Sydney 14:15 – 14:30 Screening potential skin Beyond expectations? Do Cytochrome P450 2C19 Conformational stability of sensitizers using high throughput pharmacists perform clinical genotyping cost-effective for various proteins in solid lipid direct peptide activity assay - interventions when carrying out guiding clopidogrel treatment in matrices prepared by melting 123 adherence support medication Australia - 139 and cooling - 147 Dr Sussan Ghassabian, Centre reviews? - 131 Dr Michael Sorich, Sansom Mr Farrukh Zeeshan, School of for Integrated Preclinical Drug Dr Rhiannon Braund, School of Institute, University of South Pharmacy, University of Otago, Development, University of Pharmacy, University of Otago, Australia NZ Queenland NZ 14:30– 14:45 The antimicrobial peptide LL-37 Asthma management in Liver Transplant Donor and PEGylated surfactants inhibit inhibits migration of the prostate intellectual disability (ID) - Recipient CYP3A5 and ABCB1 the digestion of co-formulated cancer cells - 124 identifying opportunities for the Genetics and Tacrolimus triglycerides in a PEG chain Ms Yan Tu, Department of pharmacist - 132 Pharmacokinetics - 140 length dependent manner - 148 Pharmacology, University of Mrs Sharon Davis, Faculty of Dr Janet Coller, Disc Miss Orlagh Feeney, Faculty of Melbourne Pharmacy, The University of Pharmacology, University of Pharmacy and Pharmaceutical Sydney Adelaide Sciences, Monash University 14:45 – 15:00 Expression and localisation Effects of three different forms Pro-migratory actions of The lymphatic system is of Pannexin-1 Hemichannels of inhaler technique education prostacyclin in breast cancer critical in maintaining the in human colon in health and for health care professionals on cells that over-express prolonged circulation of disease - 125 patient asthma outcomes - 133 cyclooxygenase-2 - 141 monoclonal antibodies and in Miss Erica Diezmos, Depts Dr Sinthia Bosnic-Anticevich, Dr Sarah Allison, promoting absorption from the of Pharmacology, School of The University of Sydney Pharmacogenomics and subcutaneous injection site - Medical Sciences, University of Drug Development, Faculty of 149 New South Wales Pharmacy, The University of Ms Annette Dahlberg, Monash Sydney Institute of Pharmaceutical Sciences, Monash University 15:00 – 15:15 Neurokinin A potentiates Community pharmacy as a A new pharmacokinetic Stabilisation of amorphous spontaneous and purinergic health hub: meeting the needs of abnormality among patients with indomethacin in aqueous evoked smooth muscle people with chronic conditions 5-fluorouracil toxicity - 142 suspensions: Effect of polymer contraction and
Load more

Recommended publications
  • Deutsche Gesellschaft Für Experimentelle Und Klinische Pharmakologie Und Toxikologie E.V
    Naunyn-Schmiedeberg´s Arch Pharmacol (2013 ) 386 (Suppl 1):S1–S104 D OI 10.1007/s00210-013-0832-9 Deutsche Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie e.V. Abstracts of the 79 th Annual Meeting March 5 – 7, 2013 Halle/Saale, Germany This supplement was not sponsored by outside commercial interests. It was funded entirely by the publisher. 123 S2 S3 001 003 Multitarget approach in the treatment of gastroesophagel reflux disease – Nucleoside Diphosphate Kinase B is a Novel Receptor-independent Activator of comparison of a proton-pump inhibitor with STW 5 G-protein Signaling in Clinical and Experimental Atrial Fibrillation Abdel-Aziz H.1,2, Khayyal M. T.3, Kelber O.2, Weiser D.2, Ulrich-Merzenich G.4 Abu-Taha I.1, Voigt N.1, Nattel S.2, Wieland T.3, Dobrev D.1 1Inst. of Pharmaceutical & Medicinal Chemistry, University of Münster Pharmacology, 1Universität Duisburg-Essen Institut für Pharmakologie, Hufelandstr. 55, 45122 Essen, Hittorfstr 58-62, 48149 Münster, Germany Germany 2Steigerwald Arzneimittelwerk Wissenschaft, Havelstr 5, 64295 Darmstadt, Germany 2McGill University Montreal Heart Institute, 3655 Promenade Sir-William-Osler, Montréal 3Faculty of Pharmacy, Cairo University Pharmacology, Cairo Egypt Québec H3G 1Y6, Canada 4Medizinische Poliklinik, University of Bonn, Wilhelmstr. 35-37, 53111 Bonn, Germany 3Medizinische Fakultät Mannheim der Universität Heidelberg Institutes für Experimentelle und Klinische Pharmakologie und Toxikologie, Maybachstr. 14, 68169 Gastroesophageal reflux disease (GERD) was the most common GI-diagnosis (8.9 Mannheim, Germany million visits) in the US in 2012 (1). Proton pump inhibitors (PPI) are presently the mainstay of therapy, but in up to 40% of the patients complete symptom control fails.
    [Show full text]
  • Biennial Report 2015 - 2017
    ANZAC Research Institute Biennial Report 2015 - 2017 1 Contents Introduction 3 About Us- Vision , Mission 4 Strategic Plan & Aspirations 5 The Organisation Reports 6 Chairman’s Report 7 Director’s Report ANZAC Research Institute Research Groups 9 Adrenal Steroid 10 Andrology 13 Atherosclerosis 14 Biogerontology 15 Bone Biology 17 Burns Research and Reconstructive Surgery 19 Dendritic Cell Research 21 Geriatric Epidemiology 22 Platelet and Thrombosis Research Lab 24 Northcott Neuroscience Laboratory 26 Vascular Biology Our Research Involvement 28 Collaborations: Summary 30 Grants & Contracts 33 Staff & Students 33 Financial Performance 34 Publications 42 Board 46 Donor Honor Roll Annual Financial Report & Independent Audit Reports Annual Financial Reports available at http://www.anzac.edu.au ANZAC Research Biennial Report 2015-17 Institute 2 About Us Vision To provide Leadership and excellence in health and medical research activities throughout Australia, with a focus on aging, to improve the future health and medical care for the Australa- sian community. In so doing, the Foundation will provide a lasting legacy to the veterans and their families who have created the society we have today. Mission To establish and operate a state-of-the-art biomedical research institute on the campus of Concord Hospital that is affiliated with the University of Sydney. To encourage, collaborate in and undertake basic, clinical and epidemiological research, with a particular focus on ageing, that aims to improve health and medical care and is dedicated to the memory of our war veterans and their families. To gain and optimise support from the wider community in order to facilitate our vision. To provide leadership and excellence in biomedical research in national and international arenas.
    [Show full text]
  • UNIVERSIDADE FEDERAL DOS VALES DO JEQUITINHONHA E MUCURI Programa De Pós Graduação Em Ciência Florestal
    UNIVERSIDADE FEDERAL DOS VALES DO JEQUITINHONHA E MUCURI Programa de Pós Graduação em Ciência Florestal Any Caroliny Pinto Rodrigues PERFIL DE EXPRESSÃO GÊNICA EM HÍBRIDOS DE Eucalyptus grandis x Eucalyptus urophylla AFETADOS PELO DISTÚRBIO FISIOLÓGICO DO EUCALIPTO (DFE) Diamantina 2020 Any Caroliny Pinto Rodrigues PERFIL DE EXPRESSÃO GÊNICA EM HÍBRIDOS DE Eucalyptus grandis x Eucalyptus urophylla AFETADOS PELO DISTÚRBIO FISIOLÓGICO DO EUCALIPTO (DFE) Tese apresentada à Universidade Federal dos Vales do Jequitinhonha e Mucuri, como parte das exigências do Programa de Pós Graduação em Ciência Florestal, área de concentração em Recursos Florestais, para obtenção do título de “Doutor”. Orientador: Prof. Dr. Marcelo Luiz de Laia Diamantina 2020 Aos meus pais e ao meu irmão por tudo que representam em minha vida e, de maneira mais especial, pelos últimos meses! Dedico com amor e gratidão! AGRADECIMENTOS Agradeço a Deus por ter sempre iluminado e guiado o meu caminho, por ter me dado fé e coragem para seguir a caminhada. Aos meus pais, Marly e Joaquim, os grandes mestres da minha vida! Agradeço o amor, apoio, incentivo e confiança incondicionais. Ao meu irmão, Thiago, que é o meu companheiro, cúmplice e melhor amigo. Agradeço por tornar sempre os meus dias mais alegres e por ter sido força quando eu mais precisei. À minha cunhada, por todo o suporte, força, ajuda e carinho que foram essenciais. A toda a minha família, em especial meus tios Marley, Flávio, Jorge e Mara, que são minha grande fonte de inspiração. A meus eternos amigos Laís (Grazy) e Luiz Paulo (Peré) que foram e são verdadeiros anjos em minha vida.
    [Show full text]
  • Intégration Des Modèles in Vitro Dans La Stratégie D'évaluation De La
    Intégration des modèles in vitro dans la stratégie d’évaluation de la sensibilisation cutanée : 2018SACLS003 Thèse de doctorat de l'Université Paris-Saclay NNT préparée à l’Université Paris-Sud École doctorale n°569 Innovation thérapeutique : du fondamental à l'appliqué Spécialité de doctorat: Immunotoxicologie Thèse présentée et soutenue à Chatenay-Malabry, le 26 Janvier 2018, par Elodie Clouet Composition du Jury : Dr. Bernard Maillère Président Directeur de Recherche, CEA (Immunochimie de la réponse immunitaire cellulaire) Pr. Armelle Baeza Rapporteur Professeur des Universités, Paris Diderot (BFA UMR CNRS 8251) Dr. Patricia Rousselle Rapporteur Directeur de Recherche, IBCP Lyon (FRE 3310, CNRS) Dr. Elena Giménez-Arnau Examinateur Chargé de Recherche, Université de Strasbourg (UMR 7177) Dr. Hervé Groux Examinateur Directeur de recherche, Immunosearch Pr. Saadia Kerdine-Römer Directrice de thèse Professeur des Universités, Université Paris-Sud (INSERM UMR-S 996) Dr. Pierre-Jacques Ferret Co-Encadrant Directeur de la Toxicologie et de la Cosmétovigilance, Pierre Fabre SOMMAIRE LISTE DES FIGURES .................................................................................................................................. 3 LISTE DES TABLEAUX ............................................................................................................................... 5 LISTE DES ABREVIATIONS ....................................................................................................................... 6 AVANT-PROPOS .....................................................................................................................................
    [Show full text]
  • Untersuchungen Zur Regulation Der Polyphenolbiosynthese in Der Erdbeerfrucht (Fragaria  Ananassa) Mittels Metabolite Profiling
    TECHNISCHE UNIVERSITÄT MÜNCHEN Fachgebiet Biotechnologie der Naturstoffe Untersuchungen zur Regulation der Polyphenolbiosynthese in der Erdbeerfrucht (Fragaria ananassa) mittels Metabolite Profiling Ludwig F. M. Ring Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technischen Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften genehmigten Dissertation. Vorsitzende: Univ.-Prof. Dr. B. Poppenberger Prüfer der Dissertation: 1. Univ.-Prof. Dr. W. Schwab 2. Univ.-Prof. Dr. Th. Hofmann 3. Univ.-Prof. Dr. D. R. Treutter Die Dissertation wurde am 17.06.2013 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 22.10.2013 angenommen. „… and all the pieces matter“ Lester Freamon, 2002 meiner Familie Danksagung I Danksagung Meinem Doktorvater Prof. Dr. Wilfried Schwab gilt mein besonderer Dank für die Überlassung des Themas und die Möglichkeit an seinem Fachgebiet zu promovieren. Außerdem danke ich ihm für seine immerwährende Unterstützung und seinen ausstrahlenden Optimismus. Bei Prof. Dr. Brigitte Poppenberger, Prof. Dr. Thomas Hofmann und Prof. Dr. Dieter Treutter bedanke ich mich für die Mitarbeit in der Prüfungskommission. Allen Kooperationspartnern des FraGenomics-Projekts, insbesondere Prof. Dr. Juan Muñoz- Blanco, Dr. Beatrice Denoyes-Rothan und Dr. Amparo Monfort, möchte ich für die gute Zusammenarbeit und die fruchtbaren Diskussionen bei den Projekttreffen danken. Prof. Dr. Victoriano Valpuesta danke ich sehr für die Möglichkeit meine Arbeiten zur Proteinanalytik am Department für Molekularbiologie und Biochemie der Universität Málaga durchführen zu können. Seinem gesamten Arbeitskreis danke ich für die herzliche Aufnahme! Gracias a todos los miembros del grupo! Además, les agradesco a Dra.
    [Show full text]
  • NSF Engineering Research Center for Biorenewable Chemicals, Third Year Renewal Proposal, Volume II NSF Engineering Research Center for Biorenewable Chemicals
    NSF Engineering Research Center for Biorenewable Center for Biorenewable Chemicals Annual Reports Chemicals 4-7-2011 NSF Engineering Research Center for Biorenewable Chemicals, Third Year Renewal Proposal, Volume II NSF Engineering Research Center for Biorenewable Chemicals Follow this and additional works at: http://lib.dr.iastate.edu/cbirc_annualreports Part of the Biomedical Engineering and Bioengineering Commons, and the Chemical Engineering Commons Recommended Citation NSF Engineering Research Center for Biorenewable Chemicals, "NSF Engineering Research Center for Biorenewable Chemicals, Third Year Renewal Proposal, Volume II" (2011). Center for Biorenewable Chemicals Annual Reports. 5. http://lib.dr.iastate.edu/cbirc_annualreports/5 This Book is brought to you for free and open access by the NSF Engineering Research Center for Biorenewable Chemicals at Iowa State University Digital Repository. It has been accepted for inclusion in Center for Biorenewable Chemicals Annual Reports by an authorized administrator of Iowa State University Digital Repository. For more information, please contact digirep@iastate.edu. NSF Engineering Research Center for Biorenewable Chemicals Transforming the THIRD YEAR RENEWALchemical PROPOSALindustry for a sustainable future VOLUME II April 7, 2011 Dr. Brent Shanks, Director Dr. Basil Nikolau, Deputy Director Core Partner Institutions Iowa State University (Lead) Rice University University of California, Irvine University of New Mexico University of Virginia University of Wisconsin Transforming the chemical
    [Show full text]
  • Biosynthesis of Lignans and Norlignans
    J Wood Sci (2007) 53:273–284 © The Japan Wood Research Society 2007 DOI 10.1007/s10086-007-0892-x REVIEW ARTICLE Shiro Suzuki · Toshiaki Umezawa Biosynthesis of lignans and norlignans Received: January 24, 2007 / Accepted: March 13, 2007 / Published online: June 5, 2007 Abstract Lignans and norlignans constitute abundant class- tic lignans in cancer therapies and sesamin in health and es of phenylpropanoids. Biosynthesis of these compounds nutrition. In addition, lignans and norlignans are often bio- has received widespread interest, mainly because they have synthesized and deposited in signifi cant amounts in the various clinically important biological activities. In addition, heartwood region of trees as a metabolic event of heart- lignans and norlignans are often biosynthesized and depos- wood formation, probably preventing heart rot by heart-rot ited in signifi cant amounts in the heartwood region of trees fungi. Because heartwood formation is specifi c to trees and as a metabolic event of heartwood formation, probably pre- does not occur in herbaceous plants, biosynthesis of lignans venting heart rot by heart-rot fungi. Furthermore, biosyn- and norlignans can be a clue to elucidating heartwood for- thetic reactions of lignans and norlignans involve unique mation mechanisms. stereochemical properties that are of great interest in terms Furthermore, biosynthetic reactions of lignans and nor- of bioorganic chemistry and are expected to provide a lignans involve unique stereochemical properties that are model for biomimetic chemistry and its application. We of great interest in terms of bioorganic chemistry and are outline the recent advances in the study of lignan and nor- expected to provide a model for biomimetic chemistry and lignan biosynthesis.
    [Show full text]
  • Eugenol and Isoeugenol, Characteristic Aromatic Constituents of Spices, Are Biosynthesized Via Reduction of a Coniferyl Alcohol Ester
    Eugenol and isoeugenol, characteristic aromatic constituents of spices, are biosynthesized via reduction of a coniferyl alcohol ester Takao Koeduka*†, Eyal Fridman*†‡, David R. Gang†§, Daniel G. Vassa˜ o¶, Brenda L. Jackson§, Christine M. Kishʈ, Irina Orlovaʈ, Snejina M. Spassova**, Norman G. Lewis¶, Joseph P. Noel**, Thomas J. Baiga**, Natalia Dudarevaʈ, and Eran Pichersky*†† *Department of Molecular, Cellular, and Developmental Biology, University of Michigan, 830 North University Street, Ann Arbor, MI 48109-1048; §Department of Plant Sciences and Institute for Biomedical Science and Biotechnology, University of Arizona, Tucson, AZ 85721-0036; ¶Institute of Biological Chemistry, Washington State University, Pullman, WA 99164-6340; ʈDepartment of Horticulture and Landscape Architecture, Purdue University, West Lafayette, IN 47907; and **Howard Hughes Medical Institute, Jack H. Skirball Chemical Biology and Proteomics Laboratory, The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037 Communicated by Anthony R. Cashmore, University of Pennsylvania, Philadelphia, PA, May 5, 2006 (received for review March 31, 2006) Phenylpropenes such as chavicol, t-anol, eugenol, and isoeugenol are produced by plants as defense compounds against animals and microorganisms and as floral attractants of pollinators. Moreover, humans have used phenylpropenes since antiquity for food pres- ervation and flavoring and as medicinal agents. Previous research suggested that the phenylpropenes are synthesized in plants from substituted phenylpropenols, although the identity of the en- zymes and the nature of the reaction mechanism involved in this transformation have remained obscure. We show here that glan- dular trichomes of sweet basil (Ocimum basilicum), which synthe- size and accumulate phenylpropenes, possess an enzyme that can use coniferyl acetate and NADPH to form eugenol.
    [Show full text]
  • European Patent Office U.S. Patent and Trademark Office
    EUROPEAN PATENT OFFICE U.S. PATENT AND TRADEMARK OFFICE CPC NOTICE OF CHANGES 89 DATE: JULY 1, 2015 PROJECT RP0098 The following classification changes will be effected by this Notice of Changes: Action Subclass Group(s) Symbols deleted: C12Y 101/01063 C12Y 101/01128 C12Y 101/01161 C12Y 102/0104 C12Y 102/03011 C12Y 103/01004 C12Y 103/0103 C12Y 103/01052 C12Y 103/99007 C12Y 103/9901 C12Y 103/99013 C12Y 103/99021 C12Y 105/99001 C12Y 105/99002 C12Y 113/11013 C12Y 113/12012 C12Y 114/15002 C12Y 114/99028 C12Y 204/01119 C12Y 402/01052 C12Y 402/01058 C12Y 402/0106 C12Y 402/01061 C12Y 601/01025 C12Y 603/02027 Symbols newly created: C12Y 101/01318 C12Y 101/01319 C12Y 101/0132 C12Y 101/01321 C12Y 101/01322 C12Y 101/01323 C12Y 101/01324 C12Y 101/01325 C12Y 101/01326 C12Y 101/01327 C12Y 101/01328 C12Y 101/01329 C12Y 101/0133 C12Y 101/01331 C12Y 101/01332 C12Y 101/01333 CPC Form – v.4 CPC NOTICE OF CHANGES 89 DATE: JULY 1, 2015 PROJECT RP0098 Action Subclass Group(s) C12Y 101/01334 C12Y 101/01335 C12Y 101/01336 C12Y 101/01337 C12Y 101/01338 C12Y 101/01339 C12Y 101/0134 C12Y 101/01341 C12Y 101/01342 C12Y 101/03043 C12Y 101/03044 C12Y 101/98003 C12Y 101/99038 C12Y 102/01083 C12Y 102/01084 C12Y 102/01085 C12Y 102/01086 C12Y 103/01092 C12Y 103/01093 C12Y 103/01094 C12Y 103/01095 C12Y 103/01096 C12Y 103/01097 C12Y 103/0701 C12Y 103/08003 C12Y 103/08004 C12Y 103/08005 C12Y 103/08006 C12Y 103/08007 C12Y 103/08008 C12Y 103/08009 C12Y 103/99032 C12Y 104/01023 C12Y 104/01024 C12Y 104/03024 C12Y 105/01043 C12Y 105/01044 C12Y 105/01045 C12Y 105/03019 C12Y 105/0302
    [Show full text]
  • Integrative Systems Biology Applied to Toxicology
    Integrative Systems Biology Applied to Toxicology Kristine Grønning Kongsbak PhD Thesis January 2015 Integrative Systems Biology Applied to Toxicology Kristine Grønning Kongsbak Søborg 2015 FOOD-PHD-2015 PhD Thesis 2015 Supervisors Professor Anne Marie Vinggaard Senior Scientist Niels Hadrup Division of Toxicology and Risk Assessment National Food Institute Technical University of Denmark Associate Professor Aron Charles Eklund Center for Biological Sequence Analysis Department for Systems Biology Technical University of Denmark Associate Professor Karine Audouze Mol´ecules Th´erapeutiques In Silico Paris Diderot University Funding This project was supported financially by the Ministry of Food, Agriculture and Fisheries of Denmark and the Technical University of Denmark. ©Kristine Grønning Kongsbak FOOD-PHD: ISBN 978-87-93109-30-8 Division of Toxicology and Risk Assessment National Food Institute Technical University of Denmark DK-2860 Søborg, Denmark www.food.dtu.dk 4 Summary Humans are exposed to various chemical agents through food, cosmetics, pharma- ceuticals and other sources. Exposure to chemicals is suspected of playing a main role in the development of some adverse health effects in humans. Additionally, European regulatory authorities have recognized the risk associated with combined exposure to multiple chemicals. Testing all possible combinations of the tens of thousands environmental chemicals is impractical. This PhD project was launched to apply existing computational systems biology methods to toxicological research. In this thesis, I present in three projects three different approaches to using com- putational toxicology to aid classical toxicological investigations. In project I, we predicted human health effects of five pesticides using publicly available data. We obtained a grouping of the chemical according to their potential human health ef- fects that were in concordance with their effects in experimental animals.
    [Show full text]
  • Budget Estimates 2020–21 Community Affairs Legislation Committee
    H E A R I N G P R O G R A M Budget Estimates 2020–21 Community Affairs Legislation Committee Monday, 26 October – Thursday, 29 October 2020 Committee Room 2S1, Parliament House, Canberra Times listed are indicative only Hearing location Committee members Committee Room 2S1, Senator Wendy Askew, Chair Parliament House, Canberra Senator Rachel Siewert, Deputy Chair Waiting room: Committee Room 2S2 Senator Helen Polley Overflow waiting room: Committee Room 1S5 Senator Andrew McLachlan Senator Malarndirri McCarthy Senator Dean Smith Ministers attending Senator the Hon Michaelia Cash Broadcasts of proceedings Senator the Hon Richard Colbeck Television channel 112 Senator the Hon Anne Ruston Radio 90.3 https://www.aph.gov.au/Watch_Read_Listen Secretariat Apolline Kohen, Committee Secretary Lorraine Watson, Estimates Officer Contact community.affairs.sen@aph.gov.au +61 2 6277 3516 Committee rooms Committee Room 2S1: (02) 6277 5843 Committee Room 2S2: (02) 6277 5851 Monday, 26 October Health Portfolio 9.00am Department of Health Whole of portfolio / Corporate matters 10.00am Outcome 1: Health System Policy, Design and Innovation Program 1.1: Health Policy Research and Analysis Program 1.2: Health Innovation and Technology Program 1.3: Health Infrastructure Program 1.4: Health Peak and Advisory Bodies Program 1.5: International Policy National Health and Medical Research Council (NHMRC) Australian Institute of Health and Welfare Australian Commission on Safety and Quality in Health Care 11.00am Break 11.15am Outcome 1: Health System Policy, Design
    [Show full text]
  • Systems Pharmacological Approach to Investigate the Mechanism of Acori Tatarinowii Rhizoma for Alzheimer’S Disease
    Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2018, Article ID 5194016, 20 pages https://doi.org/10.1155/2018/5194016 Research Article Systems Pharmacological Approach to Investigate the Mechanism of Acori Tatarinowii Rhizoma for Alzheimer’s Disease Zhenyan Song , Fang Yin, Biao Xiang, Bin Lan, and Shaowu Cheng Te Key Laboratory of Hunan Province for Integrated Traditional Chinese and Western Medicine on Prevention and Treatment of Cardio-Cerebral Diseases, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China Correspondence should be addressed to Shaowu Cheng; 702058195@qq.com Received 30 March 2018; Accepted 30 May 2018; Published 27 June 2018 Academic Editor: Ling Yang Copyright © 2018 Zhenyan Song et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In traditional Chinese medicine (TCM), Acori Tatarinowii Rhizoma (ATR) is widely used to treat memory and cognition dysfunction. Tis study aimed to confrm evidence regarding the potential therapeutic efect of ATR on Alzheimer’s disease (AD) using a system network level based in silico approach. Study results showed that the compounds in ATR are highly connected to AD-related signaling pathways, biological processes, and organs. Tese fndings were confrmed by compound-target network, target-organ location network, gene ontology analysis, and KEGG pathway enrichment analysis. Most compounds in ATR have been reported to have antifbrillar amyloid plaques, anti-tau phosphorylation, and anti-infammatory efects. Our results indicated that compounds in ATR interact with multiple targets in a synergetic way.
    [Show full text]